GlassScriptPhysician profile
Kody Dang
NPI 1518703420
$2,279.37
in general payments reported to CMS, 2019-2025
13 companies · $2,279 in 2025
The $2,279 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,279.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $833.58 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $540.65 | 2025 | Livdelzi, Vemlidy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.42 | 2025 | Xifaxan |
| Ipsen Biopharmaceuticals, INC | $177.97 | 2025 | Iqirvo |
| Abbvie INC. | $131.18 | 2025 | |
| Boston Scientific Corporation | $100.69 | 2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Mirum Pharmaceuticals, INC. | $69.43 | 2025 | Livmarli |
| Lilly USA, LLC | $62.02 | 2025 | Zepbound |
| Eisai INC. | $57.87 | 2025 | |
| Alnylam Pharmaceuticals INC. | $34.60 | 2025 | Givlaari |
| Tersera Therapeutics LLC | $31.47 | 2025 | Xermelo |
| Astrazeneca Pharmaceuticals LP | $24.39 | 2025 | |
| Novo Nordisk INC | $22.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kody Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.